Cempra, Inc. (CEMP)

[agamemnus]

They have stated they want non-dilutive funding from the start -- going back to January. My article (you skimmed over it... I know it!) says that BARDA can handle a large part of it. They are already paying over $33M for the P2/3 pediatric trial... that is almost $90K per patient. And BARDA designed a part of the safety study (we don't know how much). Why wouldn't they fund a big part of it?

They have already hired some salespeople. The jobs portal is old. If you look on LinkedIn you can find them.

It is not 2022. It is 2021, and it is sandbagging so they don't get sued. Look at my article to understand why. I don't want to keep repeating myself!

50 is probably a little light but 70 is what a few people tell me is sufficient. What is your number and reasoning?!?